Dr. Andreas K. Klein
Claim this profileTufts Medical Center
Studies Lymphoma
Studies Leukemia
9 reported clinical trials
29 drugs studied
Area of expertise
1Lymphoma
Stage IV
CD19 positive
Stage III
2Leukemia
CD19 positive
13q positive
13q negative
Affiliated Hospitals
Clinical Trials Andreas K. Klein is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting1 award Phase 21 criteria
More about Andreas K. Klein
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Andreas K. Klein has experience with
- Venetoclax
- Cyclophosphamide
- Obinutuzumab
- Nivolumab
- Doxorubicin Hydrochloride
- Radiation Therapy
Breakdown of trials Andreas K. Klein has run
Lymphoma
Leukemia
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andreas K. Klein specialize in?
Andreas K. Klein focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are CD19 positive.
Is Andreas K. Klein currently recruiting for clinical trials?
Yes, Andreas K. Klein is currently recruiting for 5 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Andreas K. Klein has studied deeply?
Yes, Andreas K. Klein has studied treatments such as Venetoclax, Cyclophosphamide, Obinutuzumab.
What is the best way to schedule an appointment with Andreas K. Klein?
Apply for one of the trials that Andreas K. Klein is conducting.
What is the office address of Andreas K. Klein?
The office of Andreas K. Klein is located at: Tufts Medical Center, Boston, Massachusetts 02111 United States. This is the address for their practice at the Tufts Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.